ArticleKidney international reports2019
Economic Burden of ESRD to the Malaysian Health Care System.
Article in Kidney international reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Disease Burden and Disparities of Care for Kidney Health in the Asian Pacific Region: Summary Report From the Diversity and Equity Committee of APSN.Nephrology (Carlton, Vic.) · 2026Review
- Medication Adherence and Clinical Outcomes among Patients with Chronic Kidney Disease: A 6-month Prospective Evaluation using Individual Adherence Assessment.Journal of research in pharmacy practice · 2026Article
- Dialysis Adequacy and Quality of Life Among Haemodialysis Patients: Does Facility Type Matter? A Comparison Between Government and Private Centres in Klang Valley, Malaysia.International journal of nephrology · 2026Article
- Multi-Omics Analysis Identified ADAM7 as a Biomarker and Therapeutic Target for End-Stage Renal Disease.Kidney & blood pressure research · 2026Article
- Comparative Assessment of Out-of-Pocket Health Expenditure in Haemodialysis and Peritoneal Dialysis Patients.Healthcare (Basel, Switzerland) · 2025Article
- Development and usability evaluation of an audio-based cognitive behavioral therapy mobile app for depression in hemodialysis patients.BMC psychology · 2025Article
- Economic burden of end stage renal disease: a case study in southern Iran.Health economics review · 2025Article
- The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Impact of pharmacist-led medication review among hemodialysis patients: a systematic review.Journal of pharmaceutical policy and practice · 2025Article
- Navigating the Global Economic Landscape of Dialysis: A Summary of Expert Opinions from The 4th International Congress of Chinese Nephrologists.Kidney diseases (Basel, Switzerland) · 2024Review
- Prevalence of diabetic kidney disease and the associated factors among patients with type 2 diabetes in a multi-ethnic Asian country.Scientific reports · 2024Article
- Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden.Kidney medicine · 2024Article
- Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden.Kidney medicine · 2024Article
- Work disability and employment status among advanced chronic kidney disease patients.PloS one · 2024Article
- Overview of global healthcare policies for patients with chronic kidney disease: an integrative literature review.Einstein (Sao Paulo, Brazil) · 2024Review
- CHA2DS2VASc score predicts risk of end stage renal disease in patients with atrial fibrillation: Long-term follow-up study.Heliyon · 2023Article
- Comparison of a chronic kidney disease predictive model for type 2 diabetes mellitus in Malaysia using Cox regression versus machine learning approach.Clinical kidney journal · 2023Article
- Determinants of microalbuminuria among type 2 diabetes mellitus patients in Kuala Selangor district: A cross-sectional study.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2022Article
- Risk of COVID-19 and Cost Burden in End-Stage Renal Disease Patients and Policy Implications for Managing Nephrology Services during the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2022Article
- Fasting Ramadan in Chronic Kidney Disease (CKD), Kidney Transplant and Dialysis Patients: Review and Update.Cureus · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevalence of chronic kidney disease (CKD) in Malaysia is 9.07% of the total population, of which 0.36% are at stage 5 CKD or end-stage renal disease (ESRD). Public-private partnership has improved accessibility of renal replacement therapies (RRT), especially dialysis, in Malaysia, but the economic burden of the existing RRT financing mechanism, which is predominantly provided by the public sector, has never been quantified.
methodsPrimary data were collected through a standardized survey, and secondary data analysis was used to derive estimates of the ESRD expenditure.
resultsTotal annual expenditure of ESRD by the public sector has grown 94% within a span of 7 years, from Malaysian Ringgit [MYR] 572 million (US dollars [USD] 405 million, purchasing power parity [PPP] 2010) in 2010 to MYR 1.12 billion (USD 785 million, PPP 2016) in 2016. The total ESRD expenditure in 2010 constituted 2.95% of the public sector's total health expenditure, whereas in 2016, the proportion has increased to 4.2%. Only 6% of ESRD expenditure was spent on renal transplantation, and the remaining 94% was spent on dialysis.
conclusionThe share of ESRD expenditure in total health expenditure for the public sector is considered substantial given only a small proportion of the population is affected by the disease. The rapid increase in expenditure relative to the national total health expenditure should warrant the relevant authorities about sustainability of the existing financing mechanism of ESRD and the importance to institutionalize more drastic preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.